Avidity Partners Management’s Immunic IMUX Stock Holding History

Avidity Partners Management’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.3M	Hold	669,941	–	–	1.65%	11
2026 Q1	$7.44M	Buy	669,941 +200,000	+43%	+$1.79M	1.51%	14
2025 Q4	$2.51M	Hold	469,941	–	–	0.72%	30
2025 Q3	$4.14M	Sell	469,941 -91,640	-16%	-$808K	0.94%	27
2025 Q2	$3.92M	Buy	561,581 +116,140	+26%	+$1.07M	0.78%	36
2025 Q1	$4.86M	Sell	445,441 -351,199	-44%	-$3.79M	0.93%	40
2024 Q4	$7.97M	Sell	796,640 -29,960	-4%	-$377K	0.78%	46
2024 Q3	$13.6M	Sell	826,600 -63,697	-7%	-$907K	0.7%	54
2024 Q2	$9.88M	Hold	890,297	–	–	0.42%	62
2024 Q1	$11.8M	Buy	+890,297	New	+$11.6M	0.38%	66

Other funds holding IMUX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Avidity Partners Management's IMUX Position: Q2 2026 in Review

Avidity Partners Management held its Immunic (IMUX) position steady in Q2 2026 at 669,941 shares worth $10.3M. The position accounts for 1.65% of the portfolio, ranked #11.

Avidity Partners Management first reported a position in IMUX in Q1 2024 and has held it in 10 quarters since. The position peaked at $13.6M in Q3 2024. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

Avidity Partners Management held 669,941 shares of Immunic worth $10.3M as of Q2 2026.
Avidity Partners Management left its Immunic share count unchanged in Q2 2026.
Immunic made up 1.65% of Avidity Partners Management's portfolio in Q2 2026, its #11 holding.
Avidity Partners Management first reported a position in Immunic in Q1 2024 and has held it in 10 quarters since.
Avidity Partners Management's Immunic position peaked at $13.6M in Q3 2024.
55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.